Authors: Olencki, T Peereboom, D Wood, L Budd, GT Novick, A Finke, J McLain, D Elson, P Bukowski, RM

Citation: T. Olencki et al., Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma, J CANC RES, 127(5), 2001, pp. 319-324

Authors: Ulchaker, J Panuto, J Rayman, P Novick, A Elson, P Tubbs, R Finke, JH Bukowski, RM

Citation: J. Ulchaker et al., Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion in response to interleukin-12, J IMMUNOTH, 22(1), 1999, pp. 71-79

Authors: Bukowski, RM Rayman, P Molto, L Tannenbaum, CS Olencki, T Peereboom, D Tubbs, R McLain, D Budd, GT Griffin, T Novick, A Hamilton, TA Finke, J

Citation: Rm. Bukowski et al., Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma, CLIN CANC R, 5(10), 1999, pp. 2780-2789

Authors: Zippe, C Pandrangi, L Potts, JM Kursh, E Novick, A Agarwal, A

Citation: C. Zippe et al., NMP22: A sensitive, cost-effective test in patients at risk for bladder cancer, ANTICANC R, 19(4A), 1999, pp. 2621-2623

Authors: Novick, A

Citation: A. Novick, Healthcare for the drug-dependent Americans, AIDS PUBL P, 13(3), 1998, pp. 97-98